A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Aspect Bio takes Novo castoff therapies; Takeda trims US jobs
Aspect Bio takes Novo castoff therapies; Takeda trims US jobs
Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI
Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons
2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
Pfizer to depart GSK's ViiV as Shionogi doubles its stake
J&J, Isomorphic sign research deal for AI-made molecules
J&J, Isomorphic sign research deal for AI-made molecules
GSK makes $2.2B deal for RAPT and its food allergy candidate
GSK makes $2.2B deal for RAPT and its food allergy candidate
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM
AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study
AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study
Drugmakers without MFN pacts are bracing to make one
Drugmakers without MFN pacts are bracing to make one
Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarin
Supreme Court will hear Hikma’s ‘skinny label’ fight against Amarin
Makary talks FDA's plans to combat China's biotech growth
Makary talks FDA's plans to combat China's biotech growth
ImmunityBio's cell therapy posts encouraging early data in rare blood cancer
ImmunityBio's cell therapy posts encouraging early data in rare blood cancer
#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026
#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026
European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA
European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
New York sues ex-Emergent CEO over insider trading during vaccine manufacturing struggle
New York sues ex-Emergent CEO over insider trading during vaccine manufacturing struggle
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page